Form 8-K Altimmune, Inc. For: Sep 23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 23, 2021

 

 

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware		001-32587		20-2726770
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
910 Clopper Road, Suite 201S Gaithersburg, Maryland				20878
(Address of principal executive offices)				(Zip Code)

 

Registrant’s telephone number including area code: (240) 654-1450

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ALT	The NASDAQ Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

 

On September 23, 2021, Altimmune, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”). As of August 10, 2021, the record date for the 2021 Annual Meeting, there were 39,705,884 shares of the Company’s common stock outstanding and entitled to vote at the 2021 Annual Meeting. A total of 28,489,957 shares of common stock were present or represented by proxy at the 2021 Annual Meeting, representing 71.75% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:

 

Proposal No. 1: Election of Directors. The results were as follows:

 

Director		For				Withhold				Broker Non-Votes
Mitchel Sayare, Ph.D.			18,420,433				392,066				9,677,458
Vipin K. Garg, Ph.D.			18,417,793				394,706				9,677,458
David J. Drutz, M.D.			15,118,630				3,693,869				9,677,458
John M. Gill			11,033,020				7,779,479				9,677,458
Philip L. Hodges			18,400,560				411,939				9,677,458
Diane Jorkasky, M.D.			18,406,747				405,752				9,677,458
Wayne Pisano			14,848,010				3,964,489				9,677,458
Klaus O. Schafer, M.D., MPH			18,400,808				411,691				9,677,458

 

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021. The results were as follows:

 

For				Against				Abstain
	28,430,498				29,266				30,193

 

Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:

 

For				Against				Abstain				Broker Non-Votes
	8,321,213				10,439,681				51,605				9,677,458

 

Proposal No. 4: Vote to authorize the adjournment of the 2021 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:

 

For				Against				Abstain
	18,509,254				9,785,811				194,892

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 24, 2021

 

	ALTIMMUNE, INC.
	By:	/s/ William Brown
		Name: William Brown
		Title: Chief Financial Officer

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alternus Clean Energy, Inc. Reports FY 2023 Financial Results
• Polybutylene Adipate Terephthalate Market to Reach USD 4.61 Billion by 2031 Fueled by Rising Demand for Sustainable Packaging and Consumer Goods
• Progress Software Corp. Statement regarding a Possible Offer for MariaDB plc